Boston – December 13, 2016 – Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced positive topline data from its Phase 2b study of CNTX-4975 in patients with knee osteoarthritis (OA) pain. In the randomized, double-blind, placebo-controlled, multicenter TRIUMPH […]

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone